Digitalis in pulmonary heart disease (cor pulmonale).
The use of digitalis in pulmonary heart disease has been a topic of great interest for a number of years. The physician's decision to use or not to use digitalis in pulmonary disease has often been an emotional rather than a reasoned one. The diagnostic difficulties from a clinical point of view in separation of pulmonary from cardiac symptoms and findings have also been confusing. The fact that small doses of digitalis may have an inotropic effect on the cardiac muscle has been a difficult concept for many physicians to adopt. On the other hand, the larger doses of digitalis that are often necessary to control the ventricular response in supraventricular arrhythmias sometimes gives rise to confusion. We shall attempt to review the subject in detail and examine indications, contraindications, toxicity, dosage, assessment of benefit, and role of digitalis serum levels in patient management.
D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D001835:Body Weight; D004071:Digitalis Glycosides / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D004077:Digoxin / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D011660:Pulmonary Heart Disease / Q000097:blood / Q000188:drug therapy*
D004071:Digitalis Glycosides; D004077:Digoxin